Latest News
New Oxford study indicates bleeding risk by aspirin in elderly patients
resTORbio begins Phase IIb mTORC1 inhibitors trial
US-based clinical-stage biopharmaceutical company PureTech Health subsidiary resTORbio has initiated a Phase IIb study of its mechanistic target of rapamycin complex 1 (mTORC1)...
BMS and Apexigen to assess Opdivo + APX005M combination for NSCLC
Bristol-Myers Squibb (BMS) has entered a clinical collaboration with biopharmaceutical firm Apexigen to assess the combination of Opdivo (nivolumab) with APX005M for the treatment of advanced...
Clinical study suggests efficacy of modafinil to improve memory in patients with depression
Sanaria reports positive results from Phase II trial of PfSPZ Vaccine for malaria
CalciMedica begins Phase I trials for CRAC channel inhibitor
US-based bio-pharmaceutical company CalciMedica has initiated the Phase I safety studies in healthy volunteers of a new calcium release-activated calcium (CRAC) channel inhibitor, CM4620,...
M&As this week: Shenzhen Neptunus Bioengineering, Korea Value Asset Management, Catalent
Shenzhen Neptunus Bioengineering plans to acquire a 70% stake in a pharmaceutical company based in Hunan,...
Deals this week: Teva Pharma, Boston Children’s Hospital, MedImmune
Teva Pharma Industries and Syqe Medical have entered an agreement to market medical cannabis inhalers in...
NIAID-funded clinical trial to evaluate shorter-duration antibiotics in children
Five medical centres in the US are planning to conduct the SCOUT-CAP clinical trial to determine the efficacy of shorter course of antibiotics in treating community-acquired pneumonia (CAP)...
NIAID to begin HVTN 702 study of new HIV vaccine regimen in South Africa
Deals this week: Rosetta Genomics, Enamine, Wuxi Biologics
Rosetta Genomics and Sheba Medical Centre have entered a research agreement to develop and evaluate the efficacy of microRNA biomarkers to analyse the response of the drug nivolumab in lung...
M&As this week: Allergen, Primex Pharmaceuticals, Cheisi Farmaceutici
Allergen has acquired Chase Pharmaceuticals Corporation from New Rhein Healthcare Investors for a purchase consideration of...
Galapagos begins DIVERSITY Phase III study of filgotinib to treat Crohn’s disease
Belgium-based clinical-stage biotechnology company Galapagos has begun its DIVERSITY Phase III study of filgotinib to treat Crohn’s disease...
Washington University and Harvard Medical School report positive topical immunotherapy trial results
Dermata Therapeutics commences treatment in Phase 2 atopic dermatitis study
Biotechnology company Dermata Therapeutics has announced the dosing of its first patient in a Phase 2 atopic dermatitis study with its lead compound DMT210. ...
Deals this week: Pfizer, Peakdale Molecular, Selexis
Pfizer and National Cancer Institute have entered a co-operative research and development (R&D) agreement to develop novel immunotherapy candidates targeting multiple...
M&As this week: Northsight Capital, GL Capital and ABG Management, Tonghua Golden Horse Pharmaceutical Industry
Northsight Capital plans to acquire Stargreen Holdings to expand its business and presence in the cannabis...
M&As this week: Sichuan Kelun Pharma, CiToxLAB
Sichuan Kelun Pharma has announced its intention to acquire stakes in two pharmaceutical companies, one based in Guangxi and another in...
Deals this week: GeoVax Labs, Yisheng Biopharma, Oryzon Genomics
GeoVax Labs and ViaMune have signed a co-development agreement for cancer immunotherapy...
M&As this week: Signal Genetics, Celldex Therapeutics
US-based molecular diagnostic company Signal Genetics is set to merge with clinical-stage biopharmaceutical company miRagen Therapeutics, with the boards of directors of both companies...
Deals this week: miRagen Therapeutics, Zhongyuan Union Cell, Health Advance
US-based biopharmaceutical company miRagen Therapeutics plans to raise $40m through private placement of its common stock shares with the help of placement agent Wedbush...
